EP4622964A4 - Chinazolinonderivate zur hdac-hemmung - Google Patents

Chinazolinonderivate zur hdac-hemmung

Info

Publication number
EP4622964A4
EP4622964A4 EP24880597.0A EP24880597A EP4622964A4 EP 4622964 A4 EP4622964 A4 EP 4622964A4 EP 24880597 A EP24880597 A EP 24880597A EP 4622964 A4 EP4622964 A4 EP 4622964A4
Authority
EP
European Patent Office
Prior art keywords
hdac inhibition
chinazolinone
derivatives
chinazolinone derivatives
hdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24880597.0A
Other languages
English (en)
French (fr)
Other versions
EP4622964A1 (de
Inventor
Chao-Wu Yu
Ji-Wang Chern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilva Therapeutics Co Ltd
Original Assignee
Gilva Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilva Therapeutics Co Ltd filed Critical Gilva Therapeutics Co Ltd
Publication of EP4622964A1 publication Critical patent/EP4622964A1/de
Publication of EP4622964A4 publication Critical patent/EP4622964A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24880597.0A 2023-10-18 2024-10-17 Chinazolinonderivate zur hdac-hemmung Pending EP4622964A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363544755P 2023-10-18 2023-10-18
PCT/US2024/051823 WO2025085669A1 (en) 2023-10-18 2024-10-17 Quinazolinone derivatives for hdac inhibition

Publications (2)

Publication Number Publication Date
EP4622964A1 EP4622964A1 (de) 2025-10-01
EP4622964A4 true EP4622964A4 (de) 2026-01-14

Family

ID=95449271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24880597.0A Pending EP4622964A4 (de) 2023-10-18 2024-10-17 Chinazolinonderivate zur hdac-hemmung

Country Status (4)

Country Link
EP (1) EP4622964A4 (de)
CN (1) CN120379970A (de)
AU (1) AU2024364867A1 (de)
WO (1) WO2025085669A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2020240493A1 (en) * 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101781922B1 (ko) * 2012-04-10 2017-09-26 안지 파마슈티컬 코퍼레이션 리미티드 히스톤 탈아세틸효소(hdacs) 억제제
EP3624804B1 (de) * 2017-05-16 2022-02-16 Annji Pharmaceutical Co., Ltd. Inhibitoren von histon-deacetylasen (hdacs)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2020240493A1 (en) * 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIEU DOAN THANH ET AL: "Design, synthesis and evaluation of novel N -hydroxybenzamides/ N -hydroxypropenamides incorporating quinazolin-4(3 H )-ones as histone deacetylase inhibitors and antitumor agents", BIOORGANIC CHEMISTRY, vol. 76, 1 February 2018 (2018-02-01), US, pages 258 - 267, XP093342779, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2017.12.007 *
KHETMALIS YOGESH MAHADU ET AL: "Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-one-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 24, no. 13, 3 July 2023 (2023-07-03), Basel, CH, pages 11044, XP093342733, ISSN: 1422-0067, DOI: 10.3390/ijms241311044 *
See also references of WO2025085669A1 *
YU WEI-CHIEH ET AL: "Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF-[beta]-Induced Idiopathic Pulmonary Fibrosis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 66, no. 15, 18 July 2023 (2023-07-18), US, pages 10528 - 10557, XP093342900, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00644> DOI: 10.1021/acs.jmedchem.3c00644 *

Also Published As

Publication number Publication date
WO2025085669A1 (en) 2025-04-24
EP4622964A1 (de) 2025-10-01
AU2024364867A1 (en) 2025-07-24
CN120379970A (zh) 2025-07-25

Similar Documents

Publication Publication Date Title
EP4320102C0 (de) Pyridazinverbindungen zur hemmung von nlrp3
EP4262803A4 (de) Tetrahydropyridopyrimidin-pan-kras-hemmer
EP4216951A4 (de) Kras-g12d-hemmer
EP4495113A4 (de) Kif18a-hemmer
EP3924352A4 (de) Kristalline formen eines rsk-hemmers
EP4007752C0 (de) Kif18a-inhibitoren
EP4007753C0 (de) Kif18a-inhibitoren
EP4434979A4 (de) Kif18a-hemmer
EP3980011A4 (de) Inhibitoren von sarm1
EP3870181A4 (de) Kristallformen eines alk2-inhibitors
EP4003986A4 (de) Hemmerverbindungen
EP4168398A4 (de) Tyk-2-inhibitor
EP4247372A4 (de) Plasmakallikreinhemmer
EP4226919A4 (de) Ferroptosehemmer
EP4210694A4 (de) Plasmakallikreinhemmer
EP3996707A4 (de) Kristalline formen von plasmakallikreininhibitoren
EP4507692A4 (de) Tryptaminderivate
EP4469457A4 (de) Substituierte heterocyclische csnk1-inhibitoren
EP4405334C0 (de) Sortilinhemmer
EP4237409A4 (de) Hdac-hemmer-festkörperformen
EP3930718A4 (de) Pyrazolopyridinverbindungen zur ire1-hemmung
EP4069229A4 (de) Festkörperformen des hdac-inhibitors
EP4499106A4 (de) Nukleosid-linie-1-inhibitoren
EP4448515A4 (de) Plpro-inhibitoren
EP3962486A4 (de) Hemmung von usp36

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0239880000

Ipc: C07D0239910000

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

A4 Supplementary search report drawn up and despatched

Effective date: 20251211

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 239/91 20060101AFI20251205BHEP

Ipc: A61P 25/00 20060101ALI20251205BHEP

Ipc: A61P 25/16 20060101ALI20251205BHEP

Ipc: A61P 25/28 20060101ALI20251205BHEP

Ipc: A61P 13/12 20060101ALI20251205BHEP

Ipc: A61P 35/00 20060101ALI20251205BHEP

Ipc: A61K 31/517 20060101ALI20251205BHEP

17Q First examination report despatched

Effective date: 20251223